<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
							<email>andreas.hochhaus@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="department">Abteilung Hämatologie/Onkologie</orgName>
								<orgName type="institution" key="instit1">Klinik für Innere Medizin II</orgName>
								<orgName type="institution" key="instit2">Universitätsklinikum Jena</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Internal Medicine &amp; Hematology</orgName>
								<orgName type="institution">University of Turin</orgName>
								<address>
									<settlement>Orbassano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">South Australian Health and Medical Research Institute (SAHMRI)</orgName>
								<orgName type="institution" key="instit2">University of Adelaide</orgName>
								<orgName type="institution" key="instit3">SA Pathology</orgName>
								<address>
									<settlement>Adelaide</settlement>
									<region>South Australia</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">The University of Chicago</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D-W</forename><surname>Kim</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Leukemia Research Institute</orgName>
								<orgName type="institution" key="instit2">Seoul St Mary&apos;s Hospital</orgName>
								<orgName type="institution" key="instit3">The Catholic University of Korea</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Issaragrisil</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Faculty of Medicine Siriraj Hospital</orgName>
								<orgName type="institution">Mahidol University</orgName>
								<address>
									<settlement>Bangkok</settlement>
									<country key="TH">Thailand</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PD</roleName><surname>Le Coutre</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Institut Bergonié</orgName>
								<orgName type="department" key="dep2">Département d&apos;Oncologie Médicale</orgName>
								<orgName type="institution">Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Clark</forename><surname>10</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Hospital das Clinicas FMUSP</orgName>
								<address>
									<settlement>São Paulo</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">Royal Liverpool University Hospital</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Flinn</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Sarah Cannon Research Institute</orgName>
								<address>
									<settlement>Nashville</settlement>
									<region>TN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Nakamae</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Osaka City University</orgName>
								<address>
									<settlement>Osaka</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Donohue</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><surname>Deng</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Dalal</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Novartis Pharmaceuticals Corporation</orgName>
								<address>
									<addrLine>East Hanover</addrLine>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Menssen</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">The University of Texas MD Anderson Cancer Center</orgName>
								<address>
									<settlement>Houston</settlement>
									<region>TX</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="department">Abteilung Hämatologie/Onkologie</orgName>
								<orgName type="institution" key="instit1">Klinik für Innere Medizin II</orgName>
								<orgName type="institution" key="instit2">Universitätsklinikum Jena</orgName>
								<address>
									<addrLine>Erlanger Allee 101</addrLine>
									<postCode>07740</postCode>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">F6FEB2D53DD51ED49717B4950B6564E3</idno>
					<idno type="DOI">10.1038/leu.2016.5</idno>
					<note type="submission">Received 2 November 2015; revised 6 January 2016; accepted 18 January 2016; accepted article preview online 3 February 2016; advance online publication, 4 March 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:16+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates and a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).</s><s>Here, patients' long-term outcomes in ENESTnd are evaluated after a minimum follow-up of 5 years.</s><s>By 5 years, more than half of all patients in each nilotinib arm (300 mg twice daily, 54%; 400 mg twice daily, 52%) achieved a molecular response 4.5 (MR 4.5  ; BCR-ABL ⩽ 0.0032% on the International Scale) compared with 31% of patients in the imatinib arm.</s><s>A benefit of nilotinib was observed across all Sokal risk groups.</s><s>Overall, safety results remained consistent with those from previous reports.</s><s>Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib.</s><s>In contrast to the high mortality rate associated with CML progression, few deaths in any arm were associated with CVEs, infections or pulmonary diseases.</s><s>These long-term results support the positive benefit-risk profile of frontline nilotinib 300 mg twice daily in patients with CML-CP.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Nilotinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) or imatinib-resistant or imatinib-intolerant Ph+ CML in CP or accelerated phase (AP). <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref></s><s>3]<ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> Nilotinib also resulted in higher rates of early molecular response (EMR; BCR-ABL IS ⩽ 10%) at 3 months, <ref type="bibr" target="#b4">5</ref> an important early indicator of efficacy, <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> and fewer treatment-emergent BCR-ABL mutations than imatinib. <ref type="bibr" target="#b7">8</ref></s><s>ecause CML-CP is a chronic disease and patients receive TKI therapy indefinitely, <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> the long-term safety of treatment must be considered.</s><s>As patients age, concurrent illnesses may develop or preexisting conditions may progress and become clinically apparent; <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> in addition, long-term TKI therapy can lead to the development of different types of adverse events (AEs) from those seen soon after initiating therapy. <ref type="bibr" target="#b5">6</ref></s><s>Thus, with multiple BCR-ABL TKIs available, <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref> physicians are called on to choose the best therapy for each individual patient.</s><s>Such decisions are informed by a detailed understanding of the distinct benefits and risks of each agent, along with careful consideration of patient-specific factors such as age and comorbidities. <ref type="bibr" target="#b5">6</ref></s><s>o enable a comprehensive evaluation of the long-term benefits and risks of nilotinib and imatinib for the treatment of patients with newly diagnosed CML-CP, here, we report updated results from ENESTnd based on a minimum follow-up of five calendar years, representing the full follow-up duration designated in the original study protocol.</s><s>ENESTnd remains ongoing, with a planned follow-up of 10 years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATIENTS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>]<ref type="bibr" target="#b11">12</ref> Briefly, adults (N = 846) within 6 months of CML-CP diagnosis and without previous CML therapy (except hydroxyurea and/or anagrelide or ⩽ 2 weeks of imatinib) and an Eastern Cooperative Oncology Group performance status of ⩽ 2 were randomized (stratified by Sokal risk score at baseline) 1:1:1 to receive nilotinib 300 mg twice daily (n = 282), nilotinib 400 mg twice daily (n = 281) or imatinib 400 mg once daily (n = 283).</s><s>ENESTnd was designed to compare each nilotinib arm with the imatinib arm but was not powered to make comparisons between the two nilotinib arms.</s><s>ENESTnd was conducted according to the principles of the Declaration of Helsinki and registered at ClinicalTrials.gov</s><s>(NCT00471497).</s><s>Written informed consent was obtained from each patient.</s><s>The study protocol was approved by the appropriate review board or ethics committee for each center.</s><s>The original trial design called for 5 years of follow-up; however, the study sponsor informed health authorities that the trial would be extended to 10 years to collect additional long-term data.</s><s>The study remains ongoing, with an active management committee.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endpoints and assessments</head><p><s>Long-term endpoints included rates of MMR, molecular response 4 (MR <ref type="bibr" target="#b3">4</ref> ; BCR-ABL IS ⩽ 0.01%) and molecular response 4.5 (MR <ref type="bibr">4.5</ref> ; BCR-ABL IS ⩽ 0.0032%); progression to accelerated phase/blast crisis (AP/BC); event-free survival (EFS); progression-free survival (PFS); overall survival (OS); and safety.</s><s>Molecular responses were assessed by BCR-ABL/ABL transcript ratios using real-time quantitative polymerase chain reaction (RQ-PCR) at a central laboratory (MolecularMD, Portland, OR, USA) standardized to the International Scale (IS), as described in the Supplementary Methods.</s><s>BCR-ABL mutations were assessed as described previously. <ref type="bibr" target="#b7">8</ref></s><s>ata on progression to AP/BC and survival were prospectively collected (including after discontinuation of study treatment) every 3 months for up to 5 years and then every 6 months (until up to 10 years after the date when the last patient started study treatment).</s><s>Time to progression to AP/ BC was defined as the time from randomization until progression to AP/BC or death due to advanced CML, whichever occurred first.</s><s>PFS was defined as the time from randomization until progression to AP/BC or death from any cause.</s><s>The rates of freedom from progression to AP/BC and of PFS on core treatment and on study were evaluated.</s><s>Rates on core treatment considered only events that occurred during treatment with the assigned study drug; rates on study considered both events that occurred during study treatment and those that occurred during follow-up after discontinuation of study treatment.</s><s>EFS was defined as the time from randomization until loss of complete hematologic response, loss of partial cytogenetic response, loss of complete cytogenetic response, progression to AP/BC or death from any cause.</s><s>EFS on core treatment was evaluated; EFS on study could not be evaluated owing to the lack of access to data regarding the loss of hematologic or cytogenetic responses following discontinuation of treatment.</s><s>OS was defined as the time from randomization until death due to any cause at any time (including during follow-up after discontinuation of study treatment).</s><s>Death due to advanced CML was defined as any death (at any time) for which the principal cause was reported by the investigator as 'study indication' (that is, due to CML) or, if subsequent to documented progression to AP/BC, any death for which the cause was reported as 'unknown' or was not reported.</s></p><p><s>Additional details regarding assessments, safety analyses and evaluation of patients' Framingham general cardiovascular risk scores are provided in the Supplementary Methods.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>All analyses were conducted on the basis of a data cutoff date of 30 September 2013 (minimum follow-up of 5 years).</s><s>Efficacy analyses included the intent-to-treat population (all randomized patients; Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>Landmark analyses included only patients with typical BCR-ABL transcripts (b2a2 and/or b3a2) <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref> at baseline, with evaluable 3-month RQ-PCR assessments, and without the analyzed outcome by 3 months.</s><s>Safety analyses included all patients who received ⩾ 1 dose of study treatment (nilotinib 300 mg twice daily, n = 279; nilotinib 400 mg twice daily, n = 277; imatinib, n = 280).</s></p><p><s>Time-to-response graphs are presented as cumulative incidence.</s><s>Patients who achieved a response at or before each time point were considered responders by that time point.</s><s>Patients with atypical transcripts (that is, transcripts other than b2a2 and/or b3a2) at baseline (nilotinib 300 mg twice daily, n = 5; nilotinib 400 mg twice daily, n = 1; imatinib, n = 2) 2 or missing RQ-PCR assessments were considered nonresponders for molecular response rates.</s><s>Response rates were compared using the Cochran-Mantel-Haenszel test stratified by Sokal risk group.</s><s>Clopper-Pearson 95% two-sided confidence intervals (CIs) for response rates were also presented.</s><s>Time-to-event variables were analyzed using the Kaplan-Meier method and were compared between groups using log-rank tests stratified by Sokal risk group.</s><s>Hazard ratios and 95% two-sided CIs were derived from a Cox model stratified by Sokal risk group; 95% CIs for Kaplan-Meier estimates were derived using the standard error calculated with Greenwood's formula.</s><s>Nominal two-sided P values, when provided, are for descriptive purposes only without multiplicity adjustments; therefore, no formal statistical claim can be made and statistical interpretation should be made with caution.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Five-year outcomes</head><p><s>At the data cutoff, 169 (59.9%), 174 (61.9%) and 141 (49.8%) patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively, remained on core treatment; more than 80% of patients in each arm remained on study (either on treatment or in follow-up after discontinuation of study treatment; Supplementary Table <ref type="table" target="#tab_3">1</ref>).</s></p><p><s>By 5 years, 217 (77.0%; 95% CI, 71.6-81.7%),</s><s>217 (77.2%; 95% CI, 71.9-82.0%)</s><s>and 171 (60.4%; 95% CI, 54.5-66.2%)</s><s>patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively, achieved MMR (Figure <ref type="figure" target="#fig_1">2a</ref>); among patients in each arm who achieved MMR at any time before the data cutoff, 13 of 218 (6.0%), 16 of 220 (7.3%) and 17 of 173 (9.8%), respectively, had a confirmed loss of first MMR (7, 9 and 10 of these patients, respectively, later regained MMR).</s><s>Very few patients without MMR by 5 years remained on core treatment at the data cutoff (5, 9 and 10 patients in the nilotinib 300-mg twicedaily, nilotinib 400-mg twice-daily and imatinib arms, respectively, including 3, 0 and 2, respectively, with atypical transcripts at baseline).</s></p><p><s>The frequency of deep molecular responses by 5 years was higher with nilotinib than with imatinib (Figures <ref type="figure" target="#fig_1">2b and c</ref>).</s><s>In the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, 185 (65.6%; 95% CI, 59.7-71.1%),</s><s>177 (63.0; 95% CI, 57.1-68.6%)</s><s>and 118 (41.7%; 95% CI, 35.9-47.7%)</s><s>patients achieved MR 4 by 5 years, respectively, and 151 (53.5%; 95% CI, 47.5-59.5%),</s><s>147 (52.3%; 95% CI, 46.3-58.3%)</s><s>and 89 (31.4%; 95% CI, 26.1-37.2%)</s><s>achieved MR <ref type="bibr">4.5</ref> , respectively.</s><s>The differences between the cumulative rates of MR <ref type="bibr">4.5</ref> in patients treated with nilotinib vs imatinib grew with each year of follow-up.</s><s>Compared with the imatinib arm, the rate of MR <ref type="bibr">4.5</ref> in the nilotinib 300-mg twice-daily arm was 16.7% higher (representing 47 more patients with MR <ref type="bibr">4.5</ref> in the nilotinib 300-mg twice-daily arm vs the imatinib arm) by 3 years, 17.1% (48 patients) higher by 4 years, and 22.1% (62 patients) higher by 5 years.</s></p><p><s>The number of progressions to AP/BC by the data cutoff was lower in both nilotinib arms vs the imatinib arm when considering either progressions occurring during treatment with the assigned study drug (that is, progressions on core treatment) or all progressions at any time during follow-up, including after discontinuation of study treatment (that is, progressions on study; Table <ref type="table" target="#tab_3">1</ref>).</s><s>No patient in any arm has progressed to AP/BC on core treatment since the 2-year analysis.</s><s>Progression to AP/BC after discontinuation of core treatment was reported in three patients between the 4-year and 5-year data cutoffs, <ref type="bibr" target="#b4">5</ref> including one patient in the nilotinib 300-mg twice-daily arm (progression reported ⩽ 28 days after discontinuation of nilotinib due to treatment failure (treatment-emergent T315I BCR-ABL mutation)) and two patients in the imatinib arm (progression for both patients reported 43 years after discontinuation of imatinib due to AE (one patient) or treatment failure (treatment-emergent D276G BCR-ABL mutation; one patient)).</s><s>All three patients had high Sokal risk scores at baseline and BCR-ABL IS 410% at 3 months.</s></p><p><s>Overall, 18, 10 and 22 deaths were reported in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively.</s><s>CML as a cause of death was more common in the imatinib arm (n = 16) than in the nilotinib arms (nilotinib 300mg twice-daily, n = 6; nilotinib 400-mg twice-daily, n = 4).</s><s>Other causes of death are shown in Figure <ref type="figure" target="#fig_2">3</ref>.</s><s>Of 50 patients who died by the data cutoff, cardiovascular events (CVEs) were reported shortly before death in three patients: two in the nilotinib 300-mg twice-daily arm and one in the imatinib arm (death occurred within 3 months of a reported CVE during study treatment in all three patients).</s><s>No patient in the nilotinib 400-mg twice-daily arm died within 3 months of a reported CVE during study treatment.</s><s>Considering all causes of death, 5-year PFS and OS rates were highest in the nilotinib 400-mg twice-daily arm (Figure <ref type="figure" target="#fig_3">4</ref>).</s></p><p><s>Treatment-emergent BCR-ABL mutations were detected in 12 (4.3%),</s><s>11 (3.9%) and 22 (7.8%) patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively, including 4 (1.4%), 2 (0.7%) and 3 (1.1%)</s><s>patients, ).</s><s>e Discontinued before receiving intervention owing to protocol deviation (n = 1), withdrawal of consent (n = 2), QTc4450 ms at baseline (n = 1).</s><s>f One patient allocated to nilotinib 400 mg twice daily received imatinib 400 mg once daily for 6 days before discontinuing intervention and was excluded from safety analysis for nilotinib 400 mg twice daily.</s><s>g Discontinued before receiving intervention owing to protocol deviation (n = 2), withdrawal of consent (n = 1), QTc4450 ms at baseline (n = 1).</s><s>h One patient allocated to nilotinib 400 mg twice daily received imatinib 400 mg once daily for 6 days before discontinuing intervention and was included in safety analysis for imatinib 400 mg once daily.</s><s>i Owing to atypical transcripts at baseline (n = 5), discontinuation prior to the month 3 assessment (n = 15), or missing month 3 assessment (n = 4).</s><s>j Owing to atypical transcripts at baseline (n = 1), discontinuation prior to the month 3 assessment (n = 17), or missing month 3 assessment (n = 3).</s></p><p><s>k Owing to atypical transcripts at baseline (n = 2), discontinuation prior to the month 3 assessment (n = 12), or missing month 3 assessment (n = 5).</s></p><p><s>respectively, with the BCR-ABL T315I mutation.</s><s>All but two BCR-ABL mutations (one in the nilotinib 300-mg twice-daily arm (T315I) and one in the imatinib arm (F317L)) were detected by the 3-year data cutoff and were previously described in detail; 8 both of the patients with a treatment-emergent BCR-ABL mutation detected after the 3-year data cutoff had high Sokal risk scores at baseline.</s></p><p><s>Nilotinib was associated with better 5-year outcomes than imatinib across all Sokal risk groups (Table <ref type="table" target="#tab_7">2</ref>).</s><s>Among patients with low, intermediate and high Sokal risk, the rates of MR <ref type="bibr">4.5</ref>   frequently in the high Sokal risk group; in the low and intermediate Sokal risk groups, no progressions to AP/BC have been reported in any arm since year 2. PFS and OS according to Sokal risk score are shown in Supplementary Figures <ref type="figure" target="#fig_1">1 and 2</ref>. As previously reported, <ref type="bibr" target="#b7">8</ref> treatment-emergent BCR-ABL mutations were detected most frequently in patients with high Sokal risk scores.</s></p><p><s>Rates of EMR and BCR-ABL IS ⩽ 1% at 3 months were higher in the nilotinib arms than in the imatinib arm. <ref type="bibr" target="#b4">5</ref></s><s>Within each arm, rates of MR 4.5 by 5 years and PFS and OS at 5 years were higher for patients with EMR or BCR-ABL IS ⩽ 1% at 3 months than for patients with BCR-ABL IS 410% at 3 months (Supplementary Table <ref type="table" target="#tab_7">2</ref>).</s><s>Treatment-emergent BCR-ABL mutations were detected in a larger proportion of patients with BCR-ABL IS 410% at 3 months (3/24 (12.5%), 2/28 (7.1%) and 14/88 (15.9%) patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively) vs EMR at 3 months (9/234 (3.8%), 9/232 (3.9%) and 8/176 (4.5%), respectively).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>The total frequencies of patients with grade 3/4 AEs, serious AEs and AEs leading to discontinuation of study treatment were comparable in the nilotinib 300-mg twice-daily (169 (60.6%), 72 (25.8%) and 34 (12.2%),</s><s>respectively) and imatinib (165 (58.9%), 71 (25.4%) and 39 (13.9%), respectively) arms, and slightly higher in the nilotinib 400-mg twice-daily arm (198 (71.5%), 91 (32.9%) and 55 (19.9%), respectively).</s><s>The most common nonhematologic AEs of any cause in both nilotinib arms were rash and headache; in the imatinib arm, diarrhea and nausea were most common (Table <ref type="table" target="#tab_8">3</ref>).</s><s>In all three treatment arms, most nonhematologic AEs were grade 1/2.</s></p><p><s>Medically severe fluid retention (namely, peripheral edema (vast majority of events in all arms), fluid retention, pleural effusion, pericardial effusion, pulmonary edema and cardiac tamponade (not reported in any arm)) was less common with nilotinib (300 mg twice daily, 11.1%; 400 mg twice daily, 14.4%) than with imatinib (23.2%).</s><s>Second malignancies were reported in 4.7%, 3.2% and 3.2% of patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively; specific types of second malignancies reported in each arm are listed in Supplementary Table <ref type="table" target="#tab_8">3</ref>. Pancreatitis and symptomatic QT prolongation were infrequent ( o3% of patients in each arm).</s><s>Hypertension was reported in 10.4%, 8.3% and 4.3% of patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily, and imatinib arms, respectively.</s><s>Very few patients in any arm developed pulmonary hypertension (n = 0 (nilotinib 300-mg twice-daily), 2 (nilotinib 400-mg twice-daily) and 0 (imatinib)) or AEs related to venous thrombosis or embolism, including retinal vein occlusion (n = 1, 0 and 0, respectively), thrombophlebitis (n = 1, 3 and 0, respectively), superficial thrombophlebitis (n = 0, 1 and 0, respectively) and deep venous thrombosis (n = 0, 1 and 1, respectively).</s><s>No case of pulmonary embolism was reported in any arm.</s><s>CVEs, namely, ischemic heart disease, ischemic cerebrovascular events and/or peripheral artery disease were reported in 21 (7.5%), 37 (13.4%) and 6 (2.1%) patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively.</s><s>Within each arm, the cumulative frequency of patients with CVEs increased linearly with time on treatment (Figure <ref type="figure">5</ref>).</s></p><p><s>To probe for the impact of preexisting cardiovascular risk on the development of CVEs during nilotinib therapy, baseline Framingham general cardiovascular risk scores <ref type="bibr" target="#b14">15</ref> were calculated for all evaluable patients (nilotinib 300 mg twice daily, n = 259; nilotinib 400 mg twice daily, n = 266; imatinib, n = 264).</s><s>The majority of patients had scores placing them in the low-risk category (that is, o10% predicted risk of experiencing a first cardiovascular disease event over 10 years (per Framingham Heart Study definition <ref type="bibr" target="#b14">15</ref> ); nilotinib 300 mg twice daily, 178 (68.7%); nilotinib 400 mg twice daily, 176 (66.2%); imatinib, 182 (68.9%)); smaller proportions of patients had scores placing them in the intermediate-risk (that is, ⩾ 10% to o 20% predicted risk of experiencing a first cardiovascular disease event over 10 years; 41 (15.8%), 52 (19.5%) and 49 (18.6%),</s><s>respectively) or high-risk (that is, ⩾ 20% predicted risk of experiencing a first cardiovascular disease event over 10 years; 40 (15.4%),</s><s>38 (14.3%) and 33 (12.5%), respectively) categories.</s><s>During study treatment, CVEs occurred most frequently among patients in the high-risk (nilotinib 300 mg twice daily, 17.5%; nilotinib 400 mg twice daily, 23.7%; imatinib, 3.0%) and intermediate-risk (12.2%, 25.0% and 4.1%, respectively) categories in each arm, whereas patients in the low-risk category in each arm experienced fewer CVEs by the data cutoff (1.7%, 6.3% and 1.1%, respectively; Supplementary Table <ref type="table">4</ref>).</s><s>Framingham general cardiovascular risk scores were evaluable for two of the three patients with deaths temporally associated with CVEs during study treatment (one patient each in the nilotinib 300-mg twice-daily and imatinib arms); both of these patients had scores in the intermediate-risk range.</s></p><p><s>Throughout 5 years of follow-up, newly occurring or worsening grade 3/4 elevations in lipase, glucose, alanine aminotransferase and bilirubin were more common in both nilotinib arms than in the imatinib arm, whereas most newly occurring or worsening grade 3/4 hematologic abnormalities (particularly neutropenia  The presence/absence of cardiovascular events (CVEs) was collected during treatment (core or extension) only.</s><s>b Death due to advanced chronic myeloid leukemia (CML) was defined as any death for which the principal cause was reported by the investigator as 'study indication' or, if subsequent to documented progression to accelerated phase/blast crisis (AP/ BC), any death for which the cause was reported as 'unknown' or was not reported.</s><s>c One patient randomized to imatinib who died prior to receiving treatment is not shown.</s><s>CABG, coronary artery bypass grafting.</s><s>and leukopenia) were more common with imatinib than with nilotinib.</s></p><p><s>Newly occurring or worsening total cholesterol elevations of any grade occurred in 77 (27.6%), 74 (26.7%) and 11 (3.9%) patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively (0, 3 (1.1%) and 0 patients, respectively, developed grade 3/4 total cholesterol elevations); newly occurring or worsening glucose elevations of any grade occurred in 139 (49.8%), 146 (52.7%) and 86 (30.7%) patients, respectively (20 (7.2%), 19 (6.9%) and 1 (0.4%) patients, respectively, developed grade 3/4 glucose elevations).</s><s>Elevations in total cholesterol, low-density lipoprotein cholesterol and glycated hemoglobin (HbA 1c ) above clinically relevant thresholds <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b17">[17]</ref><ref type="bibr" target="#b18">[18]</ref> also occurred more frequently in both nilotinib arms than in the imatinib arm (Supplementary Table <ref type="table">5</ref>).</s><s>In the nilotinib arms, cholesterol elevations tended to develop during the first year of treatment, and among evaluable patients who initiated statin therapy after developing cholesterol elevations, median cholesterol levels decreased following initiation of statin therapy (Supplementary Figure <ref type="figure" target="#fig_2">3</ref>).</s><s>The limited number of evaluable patients in all treatment arms prevented a similar analysis about the impact of antidiabetic medication in patients who developed HbA 1c elevations on study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>With 5 years of follow-up in ENESTnd, the balance of benefits and risks of nilotinib vs imatinib for the treatment of patients with newly diagnosed CML-CP can be evaluated more comprehensively than was previously possible.</s><s>]<ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> The risk of AEs (regardless of AE type) appears to be similar with nilotinib and imatinib; however, each TKI is associated with different types of AEs, including a higher risk of CVEs with nilotinib vs imatinib.</s></p><p><s>Overall and within each Sokal risk group, more patients achieved MR <ref type="bibr">4.5</ref> with nilotinib vs imatinib.</s><s>Moreover, the difference in the rates of MR <ref type="bibr">4.5</ref> with nilotinib vs imatinib increased with longer follow-up, suggesting that the benefits of nilotinib over  imatinib may become more marked over time.</s><s>Achievement of deep molecular responses such as MR 4.5 is associated with better clinical outcomes for patients with CML. <ref type="bibr" target="#b19">19,</ref><ref type="bibr" target="#b20">20</ref></s><s>In the German CML-IV study, patients with confirmed MR 4.5 at 4 years had a higher rate of 8-year OS than patients with complete cytogenetic response (CCyR) but without MMR at 4 years, and no patient who achieved MR <ref type="bibr">4.5</ref> experienced disease progression. <ref type="bibr" target="#b20">20</ref></s><s>In another study, longterm rates of EFS and failure-free survival were significantly higher among patients who achieved undetectable levels of BCR-ABL transcripts (with ⩾ 4.5-log sensitivity) than among patients who achieved CCyR without deep molecular response. <ref type="bibr" target="#b19">19</ref></s><s>Furthermore, data from clinical studies and reports of patients who have attempted treatment-free remission suggest that achievement of a deep molecular response is important for successful cessation of TKI therapy. <ref type="bibr" target="#b21">21</ref></s><s>Results from the large ENEST1st study, which evaluated MR <ref type="bibr" target="#b3">4</ref> as the primary endpoint, have confirmed the high rates of deep molecular response achieved with frontline nilotinib. <ref type="bibr" target="#b22">22</ref></s><s>The increased rates of deep molecular response achieved with nilotinib vs imatinib may allow more patients to attempt treatment-free remission in clinical trials.</s><s>Nilotinib also resulted in a rates of EMR and BCR-ABL IS ⩽ 1% at 3 months than imatinib.</s><s>]<ref type="bibr" target="#b25">[25]</ref> Treatment guidelines for CML include EMR at 3 months as the first landmark for evaluating responses to TKI therapy in patients with CML-CP. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref></s><s>The higher rate of MR 4.5 by 5 years among patients who had BCR-ABL IS ⩽ 1% at 3 months vs those who had BCR-ABL IS 41% to ⩽ 10% at 3 months suggests that early, deeper levels of molecular response may provide additional long-term benefits.</s><s>For patients with BCR-ABL IS 410% at 3 months, it is not known whether a change in therapy can improve outcomes; therefore, maximizing patients' likelihood of achieving EMR at 3 months is an important consideration during the initial management of CML-CP.</s></p><p><s>Avoiding disease progression is a primary goal of therapy for patients with CML-CP because median survival following progression is poor (≈10.5 months). <ref type="bibr" target="#b3">4</ref></s><s>Consistent with previous reports, <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> the risk of progression remained lower with nilotinib than with imatinib, and fewer patients treated with nilotinib died because of advanced CML.</s><s>Three progressions to AP/BC after discontinuation of core treatment were newly reported since the 4-year data cutoff, highlighting the fact that progression can occur at any time.</s><s>Thus, the lower risk of disease progression with nilotinib vs imatinib remains clinically important for patients receiving longterm TKI therapy, particularly for those with high Sokal risk scores or failure to achieve EMR at 3 months.</s><s>In contrast to the high mortality rate associated with disease progression, very few patients in ENESTnd died within 3 months of experiencing a CVE during study treatment (two patients in the nilotinib 300-mg twice-daily arm, none in the nilotinib 400-mg twice-daily arm and one in the imatinib arm).</s></p><p><s>]<ref type="bibr" target="#b3">[4]</ref> Notably, although both nilotinib arms showed similar efficacy, several types of AEs and laboratory abnormalities were more common with nilotinib 400 mg twice daily than with the approved dose of nilotinib 300 mg twice daily, underscoring the importance of considering dosage when evaluating TKI safety.</s><s>Overall, the rates of grade 3/4 AEs, serious AEs and AEs leading to discontinuation of study treatment were similar with nilotinib 300 mg twice daily and imatinib.</s></p><p><s>CVEs occurred more frequently with nilotinib than with imatinib, particularly in the nilotinib 400-mg twice-daily arm.</s><s>The cumulative incidence of CVEs in each arm has increased with longer follow-up.</s><s>As expected, baseline Framingham general cardiovascular risk scores were predictive of patients' risk of developing a CVE during nilotinib therapy.</s><s>7]<ref type="bibr" target="#b28">[28]</ref><ref type="bibr" target="#b29">[29]</ref> Together, our analyses and previously published data suggest that patients at risk of developing CVEs during TKI therapy might be identifiable at baseline.</s></p><p><s>Cholesterol and glucose elevations occurred more frequently in the nilotinib arms than in the imatinib arm.</s><s>However, for patients  Abbreviations: AE, adverse event; CNS, central nervous system.</s><s>a Medically severe fluid retention, hepatotoxicity, pancreatitis, significant bleeding, CNS hemorrhage, gastrointestinal hemorrhage, symptomatic QT prolongation, cardiovascular events, ischemic heart disease, ischemic cerebrovascular events and peripheral artery disease refer to predefined groupings of Medical Dictionary for Regulatory Activities (MedDRA) preferred terms or standardized MedDRA queries.</s><s>Patients with multiple events for a given AE term or category were counted only once for the AE term or category.</s><s>b No cases of cardiac tamponade were reported in any arm by the 5-year data cutoff.</s><s>c By the 5-year data cutoff, all reported symptomatic QT prolongation events were either syncope or convulsion.</s><s>The other preferred terms included in the symptomatic QT prolongation group (torsade de pointes, sudden death, ventricular tachycardia, ventricular fibrillation and ventricular flutter) were not reported in any patient by the data cutoff.</s></p><p><s>who developed cholesterol elevations while receiving nilotinib, cholesterol levels decreased following initiation of statin therapy, demonstrating the importance of active monitoring and treatment of comorbidities and cardiovascular risk factors in all patients.</s><s>Lipid-lowering therapies and/or lifestyle interventions may be indicated for some patients with sustained, low-grade cholesterol elevations. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b17">17</ref></s><s>For patients receiving TKIs who require lipid-lowering therapy, the potential for drug-drug interactions with some statins must be considered. <ref type="bibr" target="#b30">30</ref></s><s>hereas some AE types are more common with nilotinib than with imatinib, the risk of other relevant AE types, including chronic low-grade AEs and potentially serious late-onset AEs, is relatively low with nilotinib.</s><s>Edema, effusions, pulmonary hypertension and AEs related to venous thrombosis and embolism, all of which are known safety concerns associated with other BCR-ABL TKIs, <ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref> have not been frequently reported in patients treated with nilotinib.</s></p><p><s>When choosing a frontline TKI for patients with newly diagnosed CML-CP, physicians must consider the entire benefitrisk profile of each available option.</s><s>Viewed as a whole, the combined efficacy and safety results from ENESTnd demonstrate that nilotinib provided patients with meaningful long-term clinical benefits over imatinib, with a positive balance of benefit and risk, particularly with the 300-mg twice-daily dose, as frontline therapy for patients with CML-CP.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>CONSORT diagram for ENESTnd 5-year analysis (data cutoff 30 September 2013).</s><s>Efficacy analyses, including molecular and cytogenetic response rates, were based on all randomized patients (intent-to-treat population).</s><s>Safety analyses were based on patients who received ⩾ 1 dose of study treatment.</s><s>a Reasons for discontinuation: AEs/abnormal laboratory values (n = 34), suboptimal response/treatment failure (n = 34), withdrawal of consent (n = 17), death (n = 6), disease progression (n = 2), other (n = 17).</s><s>On discontinuation, 24 patients entered the extension study.</s><s>b Reasons for discontinuation: AEs/abnormal laboratory values (n = 56), withdrawal of consent (n = 16), suboptimal response/treatment failure (n = 13), disease progression (n = 4), death (n = 1), other (n = 15).</s><s>On discontinuation, three patients entered the extension study.</s><s>c Reasons for discontinuation: suboptimal response/treatment failure (n = 59), AEs/abnormal laboratory values (n = 38), withdrawal of consent (n = 17), disease progression (n = 12), death (n = 1), other (n = 12).</s><s>On discontinuation, 43 patients entered the extension study.</s><s>d Discontinued before receiving intervention owing to protocol deviation (n = 1), withdrawal of consent (n = 2).</s><s>e Discontinued before receiving intervention owing to protocol deviation (n = 1), withdrawal of consent (n = 2), QTc4450 ms at baseline (n = 1).</s><s>f One patient allocated to nilotinib 400 mg twice daily received imatinib 400 mg once daily for 6 days before discontinuing intervention and was excluded from safety analysis for nilotinib 400 mg twice daily.</s><s>g Discontinued before receiving intervention owing to protocol deviation (n = 2), withdrawal of consent (n = 1), QTc4450 ms at baseline (n = 1).</s><s>h One patient allocated to nilotinib 400 mg twice daily received imatinib 400 mg once daily for 6 days before discontinuing intervention and was included in safety analysis for imatinib 400 mg once daily.</s><s>i Owing to atypical transcripts at baseline (n = 5), discontinuation prior to the month 3 assessment (n = 15), or missing month 3 assessment (n = 4).</s><s>j Owing to atypical transcripts at baseline (n = 1), discontinuation prior to the month 3 assessment (n = 17), or missing month 3 assessment (n = 3).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Cumulative molecular response rates.</s><s>Cumulative proportion of patients with (a) major molecular response (MMR; BCR-ABL IS ⩽ 0.1%), (b) molecular response 4 (MR 4 ; BCR-ABL IS ⩽ 0.01%) and (c) molecular response 4.5 (MR 4.5 ; BCR-ABL IS ⩽ 0.0032%).</s><s>P values vs imatinib are nominal.</s><s>IS, International Scale.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Summary of deaths on study by treatment arm.</s><s>aThe presence/absence of cardiovascular events (CVEs) was collected during treatment (core or extension) only.</s><s>b Death due to advanced chronic myeloid leukemia (CML) was defined as any death for which the principal cause was reported by the investigator as 'study indication' or, if subsequent to documented progression to accelerated phase/blast crisis (AP/ BC), any death for which the cause was reported as 'unknown' or was not reported.</s><s>c One patient randomized to imatinib who died prior to receiving treatment is not shown.</s><s>CABG, coronary artery bypass grafting.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Kaplan-Meier estimated (a) progression-free survival on study and (b) overall survival on study.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Patients With MR 4.5 ,% Nilotinib 300 mg twice daily Nilotinib 400 mg twice daily Imatinib 400 mg once daily 282 281 283 n</head><label></label><figDesc><div><p><s>by 5 years in the nilotinib arms were 16.9-25.6%,</s><s>17.3-27.7%</s><s>and 19.2-21.8%</s><s>higher, respectively, than the corresponding rates in the imatinib arm.</s><s>In all three arms, progression to AP/BC occurred most</s></p></div></figDesc><table><row><cell>100</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>80</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>60</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>50</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>40</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>30</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>20</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>3</cell><cell>6</cell><cell>9</cell><cell>12</cell><cell>15</cell><cell>18</cell><cell>21</cell><cell>24</cell><cell>27</cell><cell>30</cell><cell>33</cell><cell>36</cell><cell>39</cell><cell>42</cell><cell>45</cell><cell>48</cell><cell>51</cell><cell>54</cell><cell>57</cell><cell>60</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="8">Months Since Randomization</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>100</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>80</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">By 5 Years</cell></row><row><cell>60</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">54%; P &lt; 0.0001</cell></row><row><cell>50</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">By 4 Years 40%; P &lt; 0.0001</cell><cell></cell><cell></cell><cell cols="2">52%;</cell></row><row><cell>40 30</cell><cell></cell><cell cols="3">By 1 Year 11%; P &lt; 0.0001</cell><cell cols="4">By 2 Years 25%; P &lt; 0.0001</cell><cell cols="4">By 3 Years 32%; P &lt; 0.0001</cell><cell></cell><cell cols="3">37%; P = 0.0002</cell><cell></cell><cell cols="3">P &lt; 0.0001 31%</cell></row><row><cell>20</cell><cell cols="2">7%; P &lt; 0.0001</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">19%;</cell><cell></cell><cell cols="3">28%; P = 0.0003</cell><cell></cell><cell></cell><cell cols="2">23%</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10</cell><cell>1%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">P = 0.0006</cell><cell></cell><cell></cell><cell cols="2">15%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>9%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>3</cell><cell>6 6</cell><cell>9</cell><cell>12</cell><cell>15</cell><cell>18</cell><cell>21</cell><cell>24</cell><cell>27</cell><cell>30</cell><cell>33</cell><cell>36</cell><cell>39</cell><cell>42</cell><cell>45</cell><cell>48</cell><cell>51</cell><cell>54</cell><cell>57</cell><cell>60</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="8">Months Since Randomization</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Patients With MR 4 , % Nilotinib 300 mg twice daily Nilotinib 400 mg twice daily Imatinib 400 mg once daily 282 281 283 n</head><label></label><figDesc></figDesc><table><row><cell>100</cell><cell></cell><cell></cell><cell cols="2">Nilotinib</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>80</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>60</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>50</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>40</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>30</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>20</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>10</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>3</cell><cell>6</cell><cell>9</cell><cell>12</cell><cell>15</cell><cell>18</cell><cell>21</cell><cell>24</cell><cell>27</cell><cell>30</cell><cell>33</cell><cell>36</cell><cell>39</cell><cell>42</cell><cell>45</cell><cell>48</cell><cell>51</cell><cell>54</cell><cell>57</cell><cell>60</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">By 5 Years</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">66%; P &lt; 0.0001</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">By 4 Years</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">By 3 Years</cell><cell cols="4">56%; P &lt; 0.0001</cell><cell></cell><cell></cell><cell cols="2">63%;</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">50%; P &lt; 0.0001</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">P &lt; 0.0001</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">By 2 Years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">50%;</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">39%; P &lt; 0.0001</cell><cell></cell><cell cols="3">44%; P &lt; 0.0001</cell><cell></cell><cell cols="3">P &lt; 0.0001</cell><cell></cell><cell></cell><cell cols="2">42%</cell></row><row><cell></cell><cell></cell><cell cols="3">By 1 Year</cell><cell></cell><cell></cell><cell cols="2">33%;</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">32%</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="3">20%; P &lt; 0.0001</cell><cell></cell><cell cols="3">P &lt; 0.0001</cell><cell></cell><cell></cell><cell cols="2">26%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">15%; P = 0.0004</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">18%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>6%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>300 mg twice daily Nilotinib 400 mg twice daily Imatinib 400 mg once daily 282 281 283 n Months Since Randomization Patients With MMR, %</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>By 2 Years 71%; P &lt; 0.0001</cell><cell>By 3 Years 73%; P &lt; 0.0001</cell><cell>By 4 Years 76%; P &lt; 0.0001</cell><cell>By 5 Years 77%; P &lt; 0.0001 77%; P &lt; 0.0001</cell></row><row><cell>By 1 Year</cell><cell>67%;</cell><cell>70%; P &lt; 0.0001</cell><cell>73%; P &lt; 0.0001</cell></row><row><cell>55%; P &lt; 0.0001</cell><cell>P &lt; 0.0001</cell><cell></cell><cell></cell><cell>60%</cell></row><row><cell>51%;</cell><cell></cell><cell>53%</cell><cell>56%</cell></row><row><cell>P &lt; 0.0001</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>44%</cell><cell></cell><cell></cell></row><row><cell>27%</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Long-term patient outcomes</s></p></div></figDesc><table><row><cell>Nilotinib 300 mg</cell><cell>Nilotinib 400 mg</cell><cell>Imatinib 400 mg</cell></row><row><cell>twice daily (n = 282)</cell><cell>twice daily (n = 281)</cell><cell>once daily (n = 283)</cell></row></table><note><p><s>Abbreviations: AP/BC, accelerated phase/blast crisis; CI, confidence interval; CML, chronic myeloid leukemia; EFS, event-free survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.</s><s>a Estimated by Kaplan-Meier analysis; 95% two-sided CIs for Kaplan-Meier estimates were derived using the standard error calculated with Greenwood's formula.</s><s>b HR and two-sided 95% CIs were derived from a Cox model stratified by Sokal risk group.</s><s>c Log-rank test stratified by Sokal risk group; two-sided P value is nominal.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Survival/Time to Event, Months</head><label></label><figDesc></figDesc><table><row><cell>Nilotinib</cell><cell></cell><cell>X X</cell><cell>X</cell><cell cols="2">Pneumonia Cardiac arrest (after CABG)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>300 mg</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>twice daily</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n = 18/282</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="4">Cardiogenic shock (after cardiac valve surgery)</cell><cell></cell></row><row><cell></cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nilotinib 400 mg</cell><cell></cell><cell></cell><cell>X</cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>twice daily n = 10/281</cell><cell></cell><cell></cell><cell></cell><cell>Unknown</cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>6</cell><cell>12</cell><cell>18</cell><cell>24</cell><cell>3 0</cell><cell>3 6</cell><cell>4 2</cell><cell>4 8</cell><cell>5 4</cell><cell>6 6</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Intestinal obstruction (remote history of pancreatitis, peritonitis, abdominal surgery) Suicide Ovarian adenocarcinoma Unknown Multiorgan failure Unknown Cerebrovascular accident Pneumonia Rectal carcinoma Gastric carcinoma Septic shock Carcinoma of unknown primary metastatic to brain Subdural hematoma Sepsis</head><label></label><figDesc></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Months Since Randomization Estimated Rate of PFS, % Months Since Randomization Estimated Rate of OS, %</head><label></label><figDesc></figDesc><table><row><cell>100</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>80</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>60</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>50</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>40</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>30</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Pat</cell><cell>Evt</cell><cell>Cen</cell><cell cols="4">Estimated PFS rate (95% CI) at 5 years</cell></row><row><cell>20</cell><cell></cell><cell cols="4">Nilotinib 300 mg twice daily Nilotinib 400 mg twice daily</cell><cell>282 281</cell><cell>22 11</cell><cell>260 270</cell><cell cols="2">92.2% (89.0-95.4%) 95.8% (93.4-98.3%)</cell><cell></cell><cell></cell></row><row><cell>10</cell><cell></cell><cell cols="4">Imatinib 400 mg once daily</cell><cell>283</cell><cell>24</cell><cell>259</cell><cell cols="2">91.0% (87.5-94.4%)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="3">Censored observations</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell>6</cell><cell>12</cell><cell>18</cell><cell>24</cell><cell>30</cell><cell>36</cell><cell>42</cell><cell>48</cell><cell>54</cell><cell>60</cell><cell>66</cell><cell>72</cell></row><row><cell cols="3">At-risk : Events</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nilotinib 300 mg twice daily</cell><cell>282 : 0</cell><cell></cell><cell>266 : 8</cell><cell cols="2">258 : 12</cell><cell></cell><cell>251 : 17</cell><cell></cell><cell>246 : 20</cell><cell cols="2">177 : 21</cell><cell></cell><cell>0 : 22</cell></row><row><cell>Nilotinib 400 mg twice daily</cell><cell>281 : 0</cell><cell></cell><cell>269 : 3</cell><cell></cell><cell>262 : 8</cell><cell></cell><cell>260 : 9</cell><cell></cell><cell>255 : 10</cell><cell cols="2">183 : 11</cell><cell></cell><cell>0 : 11</cell></row><row><cell>Imatinib 400 mg once daily</cell><cell>283 : 0</cell><cell></cell><cell>265 : 11</cell><cell cols="2">254 : 18</cell><cell></cell><cell>244 : 21</cell><cell></cell><cell>240 : 22</cell><cell cols="2">169 : 24</cell><cell></cell><cell>0 : 24</cell></row><row><cell>100</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>80</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>60</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>50</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>40</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>30</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Pat</cell><cell>Evt</cell><cell>Cen</cell><cell cols="4">Estimated OS rate (95% CI) at 5 years</cell></row><row><cell>20</cell><cell></cell><cell cols="4">Nilotinib 300 mg twice daily Nilotinib 400 mg twice daily</cell><cell>282 281</cell><cell>18 10</cell><cell>264 271</cell><cell cols="2">93.7% (90.8-96.6%) 96.2% (93.9-98.5%)</cell><cell></cell><cell></cell></row><row><cell>10</cell><cell></cell><cell cols="4">Imatinib 400 mg once daily</cell><cell>283</cell><cell>22</cell><cell>261</cell><cell cols="2">91.7% (88.3-95.0%)</cell><cell></cell><cell></cell></row><row><cell>0</cell><cell></cell><cell cols="3">Censored observations</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>0</cell><cell>6</cell><cell>12</cell><cell>18</cell><cell>24</cell><cell>30</cell><cell>36</cell><cell>42</cell><cell>48</cell><cell>54</cell><cell>60</cell><cell>66</cell><cell>72</cell></row><row><cell cols="3">At-risk : Events</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nilotinib 300 mg twice daily Nilotinib 400 mg twice daily Imatinib 400 mg once daily</cell><cell>282 : 0 281 : 0 283 : 0</cell><cell></cell><cell>271 : 2 270 : 2 274 : 2</cell><cell cols="2">263 : 7 264 : 6 262 : 10</cell><cell></cell><cell>254 : 13 261 : 8 250 : 16</cell><cell></cell><cell>249 : 16 256 : 9 245 : 18</cell><cell cols="2">207 : 17 206 : 10 197 : 22</cell><cell></cell><cell>1 : 18 0 : 10 0 : 22</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Five-year outcomes according to Sokal risk score BC, accelerated phase/blast crisis; MMR, major molecular response; MR4.5, molecular response 4.5 (BCR-ABL ⩽ 0.0032% on the International Scale); OS, overall survival; PFS, progression-free survival.</s><s>a Estimated by Kaplan-Meier analysis.</s><s>b Post-baseline mutational analysis in patients without baseline mutations was triggered by failure to achieve MMR at 1 year, confirmed loss of MMR, ⩾ fivefold rise in BCR-ABL transcript levels and end of treatment.</s><s>Evaluation of the frequency of treatment-emergent mutations according to Sokal risk score was exploratory.</s><s>In the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively, 48, 43 and 74 patients with low Sokal risk scores; 34, 52 and 67 patients with intermediate Sokal risk scores; and 38, 41 and 58 patients with high Sokal risk scores had post-baseline mutational analyses by the data cutoff for this analysis.</s></p></div></figDesc><table><row><cell></cell><cell>Nilotinib 300 mg twice daily</cell><cell>Nilotinib 400 mg twice daily</cell><cell>Imatinib 400 mg once daily</cell></row><row><cell>Low Sokal risk, n</cell><cell>103</cell><cell>103</cell><cell>104</cell></row><row><cell>MR 4.5 by 5 years, n (%)</cell><cell>55 (53.4)</cell><cell>64 (62.1)</cell><cell>38 (36.5)</cell></row><row><cell>Progression to AP/BC on study, n (%)</cell><cell>1 (1.0)</cell><cell>1 (1.0)</cell><cell>0</cell></row><row><cell>Estimated 5-year PFS on study, % a</cell><cell>96.0</cell><cell>99.0</cell><cell>100</cell></row><row><cell>Estimated 5-year OS on study, % a</cell><cell>97.0</cell><cell>99.0</cell><cell>100</cell></row><row><cell>Treatment-emergent mutations, n (%) b</cell><cell>1 (1.0)</cell><cell>2 (1.9)</cell><cell>1 (1.0)</cell></row><row><cell>Intermediate Sokal risk, n</cell><cell>101</cell><cell>100</cell><cell>101</cell></row><row><cell>MR 4.5 by 5 years, n (%)</cell><cell>61 (60.4)</cell><cell>50 (50.0)</cell><cell>33 (32.7)</cell></row><row><cell>Progression to AP/BC on study, n (%)</cell><cell>2 (2.0)</cell><cell>1 (1.0)</cell><cell>10 (9.9)</cell></row><row><cell>Estimated 5-year PFS on study, % a</cell><cell>92.9</cell><cell>96.9</cell><cell>87.9</cell></row><row><cell>Estimated 5-year OS on study, % a</cell><cell>93.8</cell><cell>96.9</cell><cell>88.5</cell></row><row><cell>Treatment-emergent mutations, n (%) b</cell><cell>5 (5.0)</cell><cell>3 (3.0)</cell><cell>8 (7.9)</cell></row><row><cell>High Sokal risk, n</cell><cell>78</cell><cell>78</cell><cell>78</cell></row><row><cell>MR 4.5 by 5 years, n (%)</cell><cell>35 (44.9)</cell><cell>33 (42.3)</cell><cell>18 (23.1)</cell></row><row><cell>Progression to AP/BC on study, n (%)</cell><cell>7 (9.0)</cell><cell>4 (5.1)</cell><cell>11 (14.1)</cell></row><row><cell>Estimated 5-year PFS on study, % a</cell><cell>86.2</cell><cell>90.0</cell><cell>82.6</cell></row><row><cell>Estimated 5-year OS on study, % a</cell><cell>88.8</cell><cell>91.5</cell><cell>84.2</cell></row><row><cell>Treatment-emergent mutations, n (%) b</cell><cell>6 (7.7)</cell><cell>6 (7.7)</cell><cell>13 (16.7)</cell></row><row><cell>Abbreviations: AP/</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Adverse events (regardless of relationship to study drug) and newly occurring or worsening hematologic and biochemical laboratory abnormalities reported by the data cutoff Grade 3/4 biochemical abnormalities reported in ⩾ 5% of patients in any arm, n (%)</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Nilotinib 300 mg twice daily</cell><cell cols="2">Nilotinib 400 mg twice daily</cell><cell cols="2">Imatinib 400 mg once daily</cell></row><row><cell></cell><cell>(n = 279)</cell><cell></cell><cell>(n = 277)</cell><cell></cell><cell>(n = 280)</cell><cell></cell></row><row><cell></cell><cell>Any grade</cell><cell>Grade 3/4</cell><cell>Any grade</cell><cell>Grade 3/4</cell><cell>Any grade</cell><cell>Grade 3/4</cell></row><row><cell cols="3">Nonhematologic AEs reported in ⩾ 20% of patients in any arm, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rash</cell><cell>107 (38.4)</cell><cell>2 (0.7)</cell><cell>124 (44.8)</cell><cell>7 (2.5)</cell><cell>52 (18.6)</cell><cell>5 (1.8)</cell></row><row><cell>Headache</cell><cell>89 (31.9)</cell><cell>9 (3.2)</cell><cell>100 (36.1)</cell><cell>7 (2.5)</cell><cell>64 (22.9)</cell><cell>2 (0.7)</cell></row><row><cell>Nasopharyngitis</cell><cell>75 (26.9)</cell><cell>0</cell><cell>63 (22.7)</cell><cell>0</cell><cell>60 (21.4)</cell><cell>0</cell></row><row><cell>Fatigue</cell><cell>65 (23.3)</cell><cell>3 (1.1)</cell><cell>54 (19.5)</cell><cell>4 (1.4)</cell><cell>56 (20.0)</cell><cell>4 (1.4)</cell></row><row><cell>Nausea</cell><cell>62 (22.2)</cell><cell>6 (2.2)</cell><cell>85 (30.7)</cell><cell>4 (1.4)</cell><cell>115 (41.1)</cell><cell>5 (1.8)</cell></row><row><cell>Arthralgia</cell><cell>61 (21.9)</cell><cell>1 (0.4)</cell><cell>56 (20.2)</cell><cell>2 (0.7)</cell><cell>47 (16.8)</cell><cell>1 (0.4)</cell></row><row><cell>Pruritus</cell><cell>59 (21.1)</cell><cell>1 (0.4)</cell><cell>52 (18.8)</cell><cell>1 (0.4)</cell><cell>20 (7.1)</cell><cell>0</cell></row><row><cell>Constipation</cell><cell>56 (20.1)</cell><cell>2 (0.7)</cell><cell>46 (16.6)</cell><cell>2 (0.7)</cell><cell>23 (8.2)</cell><cell>0</cell></row><row><cell>Diarrhea</cell><cell>54 (19.4)</cell><cell>3 (1.1)</cell><cell>63 (22.7)</cell><cell>7 (2.5)</cell><cell>129 (46.1)</cell><cell>10 (3.6)</cell></row><row><cell>Upper respiratory tract infection</cell><cell>47 (16.8)</cell><cell>1 (0.4)</cell><cell>59 (21.3)</cell><cell>0</cell><cell>40 (14.3)</cell><cell>0</cell></row><row><cell>Vomiting</cell><cell>42 (15.1)</cell><cell>1 (0.4)</cell><cell>56 (20.2)</cell><cell>4 (1.4)</cell><cell>75 (26.8)</cell><cell>2 (0.7)</cell></row><row><cell>Muscle spasms</cell><cell>34 (12.2)</cell><cell>0</cell><cell>32 (11.6)</cell><cell>2 (0.7)</cell><cell>95 (33.9)</cell><cell>3 (1.1)</cell></row><row><cell>Peripheral edema</cell><cell>26 (9.3)</cell><cell>2 (0.7)</cell><cell>37 (13.4)</cell><cell>0</cell><cell>56 (20.0)</cell><cell>0</cell></row><row><cell>Other AEs of interest, n (%) a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Medically severe fluid retention b</cell><cell>31 (11.1)</cell><cell>4 (1.4)</cell><cell>40 (14.4)</cell><cell>1 (0.4)</cell><cell>65 (23.2)</cell><cell>0</cell></row><row><cell>Peripheral edema</cell><cell>26 (9.3)</cell><cell>2 (0.7)</cell><cell>37 (13.4)</cell><cell>0</cell><cell>56 (20.0)</cell><cell>0</cell></row><row><cell>Pleural effusion</cell><cell>5 (1.8)</cell><cell>2 (0.7)</cell><cell>2 (0.7)</cell><cell>0</cell><cell>3 (1.1)</cell><cell>0</cell></row><row><cell>Pericardial effusion</cell><cell>2 (0.7)</cell><cell>0</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell><cell>3 (1.1)</cell><cell>0</cell></row><row><cell>Pulmonary edema</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Fluid retention</cell><cell>0</cell><cell>0</cell><cell>2 (0.7)</cell><cell>0</cell><cell>7 (2.5)</cell><cell>0</cell></row><row><cell>Second malignancies</cell><cell>13 (4.7)</cell><cell>8 (2.9)</cell><cell>9 (3.2)</cell><cell>8 (2.9)</cell><cell>9 (3.2)</cell><cell>7 (2.5)</cell></row><row><cell>Hepatotoxicity</cell><cell>5 (1.8)</cell><cell>1 (0.4)</cell><cell>15 (5.4)</cell><cell>5 (1.8)</cell><cell>7 (2.5)</cell><cell>2 (0.7)</cell></row><row><cell>Pancreatitis</cell><cell>5 (1.8)</cell><cell>1 (0.4)</cell><cell>8 (2.9)</cell><cell>2 (0.7)</cell><cell>2 (0.7)</cell><cell>0</cell></row><row><cell>Significant bleeding</cell><cell>10 (3.6)</cell><cell>3 (1.1)</cell><cell>15 (5.4)</cell><cell>5 (1.8)</cell><cell>5 (1.8)</cell><cell>1 (0.4)</cell></row><row><cell>CNS hemorrhage</cell><cell>2 (0.7)</cell><cell>1 (0.4)</cell><cell>2 (0.7)</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell></row><row><cell>Gastrointestinal hemorrhage</cell><cell>8 (2.9)</cell><cell>2 (0.7)</cell><cell>14 (5.1)</cell><cell>4 (1.4)</cell><cell>4 (1.4)</cell><cell>0</cell></row><row><cell>Hypertension</cell><cell>29 (10.4)</cell><cell>4 (1.4)</cell><cell>23 (8.3)</cell><cell>3 (1.1)</cell><cell>12 (4.3)</cell><cell>1 (0.4)</cell></row><row><cell>Pulmonary hypertension</cell><cell>0</cell><cell>0</cell><cell>2 (0.7)</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Symptomatic QT prolongation c</cell><cell>5 (1.8)</cell><cell>2 (0.7)</cell><cell>7 (2.5)</cell><cell>2 (0.7)</cell><cell>8 (2.9)</cell><cell>4 (1.4)</cell></row><row><cell>Retinal vein occlusion</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Thrombophlebitis</cell><cell>1 (0.4)</cell><cell>0</cell><cell>3 (1.1)</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Superficial thrombophlebitis</cell><cell>0</cell><cell>0</cell><cell>1 (0.4)</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Deep venous thrombosis</cell><cell>0</cell><cell>0</cell><cell>1 (0.4)</cell><cell>0</cell><cell>1 (0.4)</cell><cell>0</cell></row><row><cell>Cardiovascular events</cell><cell>21 (7.5)</cell><cell>13 (4.7)</cell><cell>37 (13.4)</cell><cell>24 (8.7)</cell><cell>6 (2.1)</cell><cell>5 (1.8)</cell></row><row><cell>Ischemic heart disease</cell><cell>11 (3.9)</cell><cell>6 (2.2)</cell><cell>24 (8.7)</cell><cell>17 (6.1)</cell><cell>5 (1.8)</cell><cell>4 (1.4)</cell></row><row><cell>Ischemic cerebrovascular event</cell><cell>4 (1.4)</cell><cell>3 (1.1)</cell><cell>9 (3.2)</cell><cell>6 (2.2)</cell><cell>1 (0.4)</cell><cell>1 (0.4)</cell></row><row><cell>Peripheral artery disease</cell><cell>7 (2.5)</cell><cell>4 (1.4)</cell><cell>7 (2.5)</cell><cell>3 (1.1)</cell><cell>0</cell><cell>0</cell></row><row><cell cols="3">Grade 3/4 hematologic abnormalities reported in ⩾ 5% of patients in any arm, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lymphopenia</cell><cell></cell><cell>35 (12.5)</cell><cell></cell><cell>23 (8.3)</cell><cell></cell><cell>40 (14.3)</cell></row><row><cell>Neutropenia</cell><cell></cell><cell>34 (12.2)</cell><cell></cell><cell>31 (11.2)</cell><cell></cell><cell>61 (21.8)</cell></row><row><cell>Thrombocytopenia</cell><cell></cell><cell>29 (10.4)</cell><cell></cell><cell>34 (12.3)</cell><cell></cell><cell>25 (8.9)</cell></row><row><cell>Anemia</cell><cell></cell><cell>11 (3.9)</cell><cell></cell><cell>13 (4.7)</cell><cell></cell><cell>18 (6.4)</cell></row><row><cell>Leukopenia</cell><cell></cell><cell>9 (3.2)</cell><cell></cell><cell>9 (3.2)</cell><cell></cell><cell>29 (10.4)</cell></row><row><cell>Increased lipase (blood)</cell><cell></cell><cell>25 (9.0)</cell><cell></cell><cell>28 (10.1)</cell><cell></cell><cell>12 (4.3)</cell></row><row><cell>Decreased phosphate</cell><cell></cell><cell>22 (7.9)</cell><cell></cell><cell>28 (10.1)</cell><cell></cell><cell>29 (10.4)</cell></row><row><cell>Increased glucose</cell><cell></cell><cell>20 (7.2)</cell><cell></cell><cell>19 (6.9)</cell><cell></cell><cell>1 (0.4)</cell></row><row><cell>Increased alanine aminotransferase</cell><cell></cell><cell>12 (4.3)</cell><cell></cell><cell>26 (9.4)</cell><cell></cell><cell>7 (2.5)</cell></row><row><cell>Increased total bilirubin</cell><cell></cell><cell>12 (4.3)</cell><cell></cell><cell>25 (9.0)</cell><cell></cell><cell>1 (0.4)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2016 Macmillan Publishers LimitedLeukemia (2016) 1044 -1054</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Leukemia (2016) 1044 -1054 © 2016 Macmillan Publishers Limited</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>Authors declare the following relationships with pharmaceutical companies: Novartis -receipt of honoraria (AH, GS, TPH, DWK, PdlC, GE, REC, HN), research funding (all authors), nonfinancial support (GE, HN), employment (BD, WD, DD, HDM) and stock ownership (BD, DD, HDM); Pfizer-receipt of honoraria (AH, RAL, PdlC, GE, REC) and research funding (AH, DWK, REC); Ariad-receipt of honoraria (AH, TPH, GS, PdlC, GE) and research funding (AH, TPH); Bristol-Myers Squibb-receipt of honoraria (AH, GS, TPH, DWK, PdlC), research funding (AH, TPH, REC, IWF) and nonfinancial support (GE); Sanofi-receipt of honoraria (REC) and research funding (REC); Ilyang-receipt of honoraria (DWK).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p><s>The ENESTnd study and work presented here were sponsored and funded by Novartis Pharmaceuticals Corporation.</s><s>Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.</s><s>We thank Karen Kaluza, PhD, and Staci Heise, PhD (Articulate Science), for medical editorial assistance with this manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The shaded portion of the graph shows censored data and events that occurred after 60 months of treatment and up to the data cutoff date.</s><s>Because patients had variable follow-up durations beyond the 60-month time point at the data cutoff for this exploratory analysis, the shaded portion of the graph does not fully reflect outcomes after 60 months of treatment exposure.</s></p><p><s>Frontline nilotinib vs imatinib for CML A Hochhaus et al Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)</s><s>Frontline nilotinib vs imatinib for CML</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<author>
			<persName><surname>Tasigna</surname></persName>
		</author>
		<title level="m">Novartis Pharmaceuticals Corporation: East Hanover</title>
				<meeting><address><addrLine>NJ, USA</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>package insert</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Issaragrisil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Le Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Etienne</forename><forename type="middle">G</forename><surname>Lobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="2251" to="2259" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Flinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Stenke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="841" to="851" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2197" to="2203" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Niederwieser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="1353" to="1360" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">European LeukemiaNet recommendations for the management of chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Deininger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Soverini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Apperley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="872" to="884" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia</title>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="3703" to="3708" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Longitudinal effects of a decade of aging on carotid artery stiffness: the multiethnic study of atherosclerosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Gepner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Korcarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Colangelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Hom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Tattersall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Astor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="48" to="53" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prevalence of coronary atherosclerosis in asymptomatic healthy subjects: an intravascular ultrasound study of donor hearts</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Atheroscler Thromb</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="465" to="471" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Treatmentdependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">T</forename><surname>Wilke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Groth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fuchs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Seitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kienhöfer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Diabetol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cervantes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Niederwieser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="1204" to="1211" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giannoudis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Knight</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Watmough</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1362" to="1367" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Melo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="186" to="189" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">General cardiovascular risk profile for use in primary care: the Framingham Heart Study</title>
		<author>
			<persName><forename type="first">D'agostino Rb</forename><surname>Sr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Vasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Pencina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cobain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Massaro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="743" to="753" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Perk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Backer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gohlke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Reiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ž</forename><surname>Verschuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Guidelines on cardiovascular disease prevention in clinical</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)</title>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1635" to="1701" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Lichtenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bairey</forename><surname>Merz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Eckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="S1" to="S45" />
			<date type="published" when="2013">2013. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Standards of medical care in diabetes-2011</title>
	</analytic>
	<monogr>
		<title level="j">Diabetes Care</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="S11" to="S61" />
			<date type="published" when="2011">2011</date>
			<publisher>American Diabetes Association</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dulucq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morrisset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Fort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="458" to="464" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hehlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hanfstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fabarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schreiber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="415" to="423" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Deep molecular response in chronic myeloid leukemia: the new goal of therapy?</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Mahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="310" to="322" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ncp</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Steegmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Le Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ossenkoppele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="57" to="64" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gerrard</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Szydlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="232" to="238" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities</title>
		<author>
			<persName><forename type="first">P</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nazha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jabbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Romo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="4867" to="4874" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Early molecular and cytogenetic response is predictive for long-term progressionfree and overall survival in chronic myeloid leukemia (CML)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hanfstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hehlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Erben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fabarius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2096" to="2102" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or nontyrosine kinase therapy: a retrospective cohort analysis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Ortmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mcneill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Woodman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1310" to="1315" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1316" to="1321" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gambacorti-Passerini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lipton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dmoszynska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rossiev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="947" to="953" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Molica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Zacheo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Serrao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alimena</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="393" to="397" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib</title>
		<author>
			<persName><forename type="first">A</forename><surname>Haouala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Widmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Duchosal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montemurro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Buclin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Decosterd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="e75" to="e87" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Jabbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Steegmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boqué</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="494" to="500" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Pulmonary arterial hypertension in patients treated by dasatinib</title>
		<author>
			<persName><forename type="first">D</forename><surname>Montani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bergot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Günther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Savale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bourdin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="2128" to="2137" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article&apos;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material</title>
		<author>
			<persName><surname>Iclusig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">ARIAD Pharmaceuticals</title>
				<meeting><address><addrLine>Cambridge, MA, USA</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>package insert. To view a copy of this license, visit http://</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
